We demonstrated that lomitapide markedly improves antitumor responses conferred by anti-PD-1 administration in syngeneic colon cancer MC38 and melanoma B16-F10 models, thereby potentially extending the scope for its potential use in combination with other therapies. Here, PDCD1 is linked to colonic neoplasm.